Soluble CD163 is a predictor of fibrosis and hepatocellular carcinoma development in nonalcoholic steatohepatitis
Abstract Background Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease. The serum level of soluble CD163 (sCD163), a macrophage activation marker, is associated with liver tissue changes; however, its prognostic value is unknown. Here, we determined the utilit...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-05-01
|
| Series: | BMC Gastroenterology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12876-023-02786-4 |
| _version_ | 1797827504638001152 |
|---|---|
| author | Miwa Kawanaka Ken Nishino Mayuko Kawada Katsunori Ishii Tomohiro Tanikawa Ryo Katsumata Noriyo Urata Jun Nakamura Mitsuhiko Suehiro Ken Haruma Hirofumi Kawamoto |
| author_facet | Miwa Kawanaka Ken Nishino Mayuko Kawada Katsunori Ishii Tomohiro Tanikawa Ryo Katsumata Noriyo Urata Jun Nakamura Mitsuhiko Suehiro Ken Haruma Hirofumi Kawamoto |
| author_sort | Miwa Kawanaka |
| collection | DOAJ |
| description | Abstract Background Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease. The serum level of soluble CD163 (sCD163), a macrophage activation marker, is associated with liver tissue changes; however, its prognostic value is unknown. Here, we determined the utility of sCD163 as a marker for hepatocellular carcinoma (HCC) and prognostic marker for NAFLD. Methods This retrospective study obtained data regarding serum sCD163 levels, liver histology, and background factors associated with NAFLD in 287 patients (men/women, 140/147; average age, 53 ± 14 years) with NAFLD who underwent liver biopsy. Repeated liver biopsies of 287 patients with NAFLD (5.0 ± 2.7 years) were compared regarding serum sCD163 levels and liver tissue changes (stage, grade, steatosis, and NAFLD activity score). Results Serum sCD163 levels increased with the progression of liver fibrosis and inflammation (both P < 0.05) and were particularly helpful in distinguishing cases of Grade 4 fibrosis (P < 0.001). Levels of sCD163 significantly decreased in patients with NAFLD exhibiting alleviated fibrosis and inflammation (P < 0.05). We could also predict the development of HCC and associated mortality based on serum sCD163 levels at the time of NAFLD diagnosis. Serum sCD163 levels were higher in patients with HCC than in patients without HCC (1074 ± 379 ng/ml vs. 669 ± 261 ng/ml; P < 0.0001), and the same trend was observed for mortality. Conclusions The serum sCD163 level reflects the progression of fibrosis and inflammation in liver tissues, showing much promise as a noninvasive biomarker for nonalcoholic steatohepatitis and NAFLD as well as a possible predictor of HCC development and patient prognosis. |
| first_indexed | 2024-04-09T12:49:23Z |
| format | Article |
| id | doaj.art-5f811a5303754d05a9c8628516ed76b5 |
| institution | Directory Open Access Journal |
| issn | 1471-230X |
| language | English |
| last_indexed | 2024-04-09T12:49:23Z |
| publishDate | 2023-05-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Gastroenterology |
| spelling | doaj.art-5f811a5303754d05a9c8628516ed76b52023-05-14T11:18:45ZengBMCBMC Gastroenterology1471-230X2023-05-012311910.1186/s12876-023-02786-4Soluble CD163 is a predictor of fibrosis and hepatocellular carcinoma development in nonalcoholic steatohepatitisMiwa Kawanaka0Ken Nishino1Mayuko Kawada2Katsunori Ishii3Tomohiro Tanikawa4Ryo Katsumata5Noriyo Urata6Jun Nakamura7Mitsuhiko Suehiro8Ken Haruma9Hirofumi Kawamoto10Department of General Internal Medicine, General Medical Center, Kawasaki Medical SchoolDepartment of General Internal Medicine, General Medical Center, Kawasaki Medical SchoolDepartment of General Internal Medicine, General Medical Center, Kawasaki Medical SchoolDepartment of General Internal Medicine, General Medical Center, Kawasaki Medical SchoolDepartment of General Internal Medicine, General Medical Center, Kawasaki Medical SchoolDepartment of General Internal Medicine, General Medical Center, Kawasaki Medical SchoolDepartment of General Internal Medicine, General Medical Center, Kawasaki Medical SchoolDepartment of General Internal Medicine, General Medical Center, Kawasaki Medical SchoolDepartment of General Internal Medicine, General Medical Center, Kawasaki Medical SchoolDepartment of General Internal Medicine, General Medical Center, Kawasaki Medical SchoolDepartment of General Internal Medicine, General Medical Center, Kawasaki Medical SchoolAbstract Background Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease. The serum level of soluble CD163 (sCD163), a macrophage activation marker, is associated with liver tissue changes; however, its prognostic value is unknown. Here, we determined the utility of sCD163 as a marker for hepatocellular carcinoma (HCC) and prognostic marker for NAFLD. Methods This retrospective study obtained data regarding serum sCD163 levels, liver histology, and background factors associated with NAFLD in 287 patients (men/women, 140/147; average age, 53 ± 14 years) with NAFLD who underwent liver biopsy. Repeated liver biopsies of 287 patients with NAFLD (5.0 ± 2.7 years) were compared regarding serum sCD163 levels and liver tissue changes (stage, grade, steatosis, and NAFLD activity score). Results Serum sCD163 levels increased with the progression of liver fibrosis and inflammation (both P < 0.05) and were particularly helpful in distinguishing cases of Grade 4 fibrosis (P < 0.001). Levels of sCD163 significantly decreased in patients with NAFLD exhibiting alleviated fibrosis and inflammation (P < 0.05). We could also predict the development of HCC and associated mortality based on serum sCD163 levels at the time of NAFLD diagnosis. Serum sCD163 levels were higher in patients with HCC than in patients without HCC (1074 ± 379 ng/ml vs. 669 ± 261 ng/ml; P < 0.0001), and the same trend was observed for mortality. Conclusions The serum sCD163 level reflects the progression of fibrosis and inflammation in liver tissues, showing much promise as a noninvasive biomarker for nonalcoholic steatohepatitis and NAFLD as well as a possible predictor of HCC development and patient prognosis.https://doi.org/10.1186/s12876-023-02786-4Nonalcoholic fatty liver diseaseSoluble CD163Hepatocellular carcinomaCirrhosisPrognosis |
| spellingShingle | Miwa Kawanaka Ken Nishino Mayuko Kawada Katsunori Ishii Tomohiro Tanikawa Ryo Katsumata Noriyo Urata Jun Nakamura Mitsuhiko Suehiro Ken Haruma Hirofumi Kawamoto Soluble CD163 is a predictor of fibrosis and hepatocellular carcinoma development in nonalcoholic steatohepatitis BMC Gastroenterology Nonalcoholic fatty liver disease Soluble CD163 Hepatocellular carcinoma Cirrhosis Prognosis |
| title | Soluble CD163 is a predictor of fibrosis and hepatocellular carcinoma development in nonalcoholic steatohepatitis |
| title_full | Soluble CD163 is a predictor of fibrosis and hepatocellular carcinoma development in nonalcoholic steatohepatitis |
| title_fullStr | Soluble CD163 is a predictor of fibrosis and hepatocellular carcinoma development in nonalcoholic steatohepatitis |
| title_full_unstemmed | Soluble CD163 is a predictor of fibrosis and hepatocellular carcinoma development in nonalcoholic steatohepatitis |
| title_short | Soluble CD163 is a predictor of fibrosis and hepatocellular carcinoma development in nonalcoholic steatohepatitis |
| title_sort | soluble cd163 is a predictor of fibrosis and hepatocellular carcinoma development in nonalcoholic steatohepatitis |
| topic | Nonalcoholic fatty liver disease Soluble CD163 Hepatocellular carcinoma Cirrhosis Prognosis |
| url | https://doi.org/10.1186/s12876-023-02786-4 |
| work_keys_str_mv | AT miwakawanaka solublecd163isapredictoroffibrosisandhepatocellularcarcinomadevelopmentinnonalcoholicsteatohepatitis AT kennishino solublecd163isapredictoroffibrosisandhepatocellularcarcinomadevelopmentinnonalcoholicsteatohepatitis AT mayukokawada solublecd163isapredictoroffibrosisandhepatocellularcarcinomadevelopmentinnonalcoholicsteatohepatitis AT katsunoriishii solublecd163isapredictoroffibrosisandhepatocellularcarcinomadevelopmentinnonalcoholicsteatohepatitis AT tomohirotanikawa solublecd163isapredictoroffibrosisandhepatocellularcarcinomadevelopmentinnonalcoholicsteatohepatitis AT ryokatsumata solublecd163isapredictoroffibrosisandhepatocellularcarcinomadevelopmentinnonalcoholicsteatohepatitis AT noriyourata solublecd163isapredictoroffibrosisandhepatocellularcarcinomadevelopmentinnonalcoholicsteatohepatitis AT junnakamura solublecd163isapredictoroffibrosisandhepatocellularcarcinomadevelopmentinnonalcoholicsteatohepatitis AT mitsuhikosuehiro solublecd163isapredictoroffibrosisandhepatocellularcarcinomadevelopmentinnonalcoholicsteatohepatitis AT kenharuma solublecd163isapredictoroffibrosisandhepatocellularcarcinomadevelopmentinnonalcoholicsteatohepatitis AT hirofumikawamoto solublecd163isapredictoroffibrosisandhepatocellularcarcinomadevelopmentinnonalcoholicsteatohepatitis |